(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.12%.
Lexaria Bioscience's earnings in 2025 is -$11,901,841.On average, 5 Wall Street analysts forecast LEXX's earnings for 2026 to be -$11,788,589, with the lowest LEXX earnings forecast at -$14,811,304, and the highest LEXX earnings forecast at -$7,934,627. On average, 4 Wall Street analysts forecast LEXX's earnings for 2027 to be -$17,002,772, with the lowest LEXX earnings forecast at -$25,484,155, and the highest LEXX earnings forecast at -$7,701,256.
In 2028, LEXX is forecast to generate $2,720,444 in earnings, with the lowest earnings forecast at $2,613,759 and the highest earnings forecast at $2,800,457.